These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6233982)

  • 1. Coronary thrombolysis: pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA).
    Fox KA; Bergmann SR; Sobel BE
    Biochem Pharmacol; 1984 Jun; 33(12):1831-8. PubMed ID: 6233982
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular mechanisms of thrombolytic therapy].
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring activity of fibrinolytic agents. A therapeutic challenge.
    Shafer KE; Santoro SA; Sobel BE; Jaffe AS
    Am J Med; 1984 May; 76(5):879-86. PubMed ID: 6232847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
    Marder VJ; Francis CW
    Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729
    [No Abstract]   [Full Text] [Related]  

  • 8. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards.
    Brommer EJ
    Thromb Res; 1984 Apr; 34(2):109-15. PubMed ID: 6539513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
    Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the fibrinolytic system.
    Robison AK; Collen D
    Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M; Zenker M; Klinge J; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 19. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 20. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase.
    Sumi H; Takada Y; Takada A
    Nihon Seirigaku Zasshi; 1977; 39(5):112-4. PubMed ID: 72149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.